MADISON, Wis.–(BUSINESS WIRE)–FDA approves Promega OncoMate® MSI Dx Analysis System as companion diagnostic for KEYTRUDA® (pembrolizumab) in MSI-High solid tumors.

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.